Results from the BIONYX Trial found the Resolute Onyx stent provided better x-ray visibility compared to Orsiro, an established cobalt-chromium strut stent, according to findings presented Monday, Sept. 24 at the Transcatheter Cardiovascular Therapeutics (TCT) symposium in San Diego.
Developed in response to an increased demand for stents with improved radiographic abilities, Resolute Onyx is a polymer-coated zotarolimus-eluting stent now proven safe and effective in an all-comer group of more than 2,000 patients, reported lead investigator Clemens von Birgelen, MD, PhD, in a release. The metallic stent platform uses a dense platinum-iridium core to make its struts more radiopaque.
“The vast majority of contemporary stents use stent platforms from cobalt-chromium alloy, which allows for the creation of fine mesh tubes with satisfactory radial force but limited x-ray visibility,” von Birgelen said. “Suboptimal radiographic visibility can be challenging in obese patients, when treating bifurcated or calcified coronary lesions or when carefully assessing stent expansion.”
Von Birgelen and colleagues included 2,488 all-comer patients in their intent-to-treat analysis. All were between 30 and 96 years old, with a majority being treated for acute coronary syndrome. Fifty-one percent were treated for acute myocardial infarction.
Results were similar among patients, with little difference between those who received the Resolute Onyx or Orsiro stent. At one year follow-up, 4.5 percent of patients with Onyx achieved the primary endpoint of target vessel failure—4.7 percent met that endpoint in the Orsiro group.
“Treatment with both stents was similarly safe and effective with excellent one-year clinical outcomes in a complex all-comer patient population,” Von Birgelen added in the statement.
The study was also published online Sept. 24 in The Lancet.